Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Cushing Syndrome 2ACTH Syndrome, Ectopic 2Adrenal Hyperplasia, Congenital 1Adrenal Cortex Neoplasms 1Acth-Independent Macronodular Adrenal Hyperplasia 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Osilodrostat × Clear all
NCT07104812 2026-02-11

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Mayo Clinic

Phase 2 Recruiting
15 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

NCT02468193 2020-05-06

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Novartis

Phase 2 Completed
9 enrolled 22 charts

Acth-Independent Macronodular Adrenal Hyperplasia, ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡